期刊
JOURNAL OF DRUG TARGETING
卷 23, 期 7-8, 页码 605-618出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/1061186X.2015.1052072
关键词
CD44 biology; CD44/HA targeting; drug delivery; hyaluronic acid; nanoparticles
资金
- National Cancer Institute of the National Institutes of Health [U01-CA151452, R21-CA179652]
- NATIONAL CANCER INSTITUTE [U01CA151452, R21CA179652] Funding Source: NIH RePORTER
Cluster of differentiation-44 (CD44) is a ubiquitously present glycoprotein on the surface of mammalian cells that plays a significant role in a number of biological functions. Since the discovery that the receptor is over-expressed in a variety of solid tumors, such as pancreatic, breast and lung cancer, many studies have focused on methods for targeting CD44 in an attempt to improve drug delivery and discrimination between healthy and malignant tissue, while reducing residual toxicity and off-target accumulation. In this review, we describe CD44 receptor biology and its involvement in the different stages of tumor growth and metastasis, as well as methods currently used for targeting the receptor. Hyaluronic acid, the primary CD44 binding molecule, has proved a significant ally in developing nanocarriers that demonstrate preferential tumor accumulation and increased cell uptake. We outline a number of research approaches from the current literature that take advantage of hyaluronic acid's targeting ability and describe the possible advantages for each approach. The value of CD44 targeting can be easily appreciated from the number of different approaches that have reached clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据